For example, the study by Vojdani et al. [50], conducted with a control group of similar age (32–48 years), detected similar levels of antibodies to MBP, as was shown in our current study, in contrast to its threefold increase in MS patients. The gene discussed is MBP; the disease is myeloid sarcoma.